IMMX (STOCKS)
Immix Biopharma, Inc. Common Stock
$8.680000
+0.230000 (+2.72%)
Prev close: $8.450000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ilya Rachman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $602.98M
- Employees
- 21
- P/E (TTM)
- -9.21
- P/B (TTM)
- 5.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.18 | $-0.21 | +0.0324 | +15.25% |
|
Dec 2025 (Q4)
|
$-0.28 | $-0.16 | -0.1209 | -75.99% |
|
Sep 2025 (Q3)
|
$-0.24 | $-0.19 | -0.0462 | -23.84% |
|
Jun 2025 (Q2)
|
$-0.22 | $-0.16 | -0.0568 | -34.80% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $1.12M |
| Operating Expenses | $36.08M |
| Research and Development | $20.26M |
| Other Operating Expenses | $15.81M |
| Operating Income/Loss | -$36.08M |
| Income/Loss From Continuing Operations After Tax | -$34.94M |
| Income/Loss From Continuing Operations Before Tax | -$34.95M |
| Net Income/Loss | -$35.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$13.31K |
| Net Income/Loss Attributable To Parent | -$34.94M |
| Net Income/Loss Available To Common Stockholders, Basic | -$34.94M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.92 |
| Diluted Earnings Per Share | -$0.92 |
| Basic Average Shares | 119,699,067 |
| Diluted Average Shares | 119,699,067 |
| Assets | $95.82M |
| Current Assets | $92.27M |
| Cash | $90.60M |
| Other Current Assets | $1.67M |
| Noncurrent Assets | $3.54M |
| Fixed Assets | $2.43M |
| Other Non-current Assets | $1.11M |
| Liabilities | $11.45M |
| Current Liabilities | $10.54M |
| Accounts Payable | $4.73M |
| Wages | $880.67K |
| Other Current Liabilities | $4.93M |
| Noncurrent Liabilities | $912.34K |
| Equity | $84.36M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $84.36M |
| Liabilities And Equity | $95.82M |
| Net Cash Flow From Operating Activities | -$32.07M |
| Net Cash Flow From Operating Activities, Continuing | -$32.07M |
| Net Cash Flow From Investing Activities | -$11.95M |
| Net Cash Flow From Investing Activities, Continuing | -$11.95M |
| Net Cash Flow From Financing Activities | $120.27M |
| Net Cash Flow From Financing Activities, Continuing | $120.26M |
| Exchange Gains/Losses | -$971.00 |
| Net Cash Flow | $76.25M |
| Net Cash Flow, Continuing | $76.25M |
| Comprehensive Income/Loss | -$34.89M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$34.96M |
| Other Comprehensive Income/Loss | -$7.30K |
| Other Comprehensive Income/Loss Attributable To Parent | $90.17K |